Business Context and Reporting Period
Company: Intrexon Corporation (formerly Intrexon Corporation, now operating as Intrexon Corporation following a name change noted in the filing header, though the text refers to Intrexon Corporation throughout). The company is a synthetic biology firm that designs, builds, and regulates gene programs to create products for healthcare, food, energy, and environmental sciences.
Reporting Period: Quarterly period ended June 30, 2013 (Form 10-Q).
Key Operational Update: On March 15, 2013, Intrexon acquired additional shares of AquaBounty Technologies, Inc., increasing its ownership to 53.82% and gaining control. AquaBounty's financial results have been consolidated into Intrexon's statements beginning March 15, 2013. The company completed its Initial Public Offering (IPO) on August 13, 2013, subsequent to the reporting period.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2013 | Six Months Ended June 30, 2012 |
|---|---|---|
| Total Revenues | $10.8 million | $4.3 million |
| Operating Loss | $(28.3) million | $(46.4) million |
| Net Loss | $(42.9) million | $(30.4) million |
| Net Loss Attributable to Common Shareholders | $(56.7) million | $(41.3) million |
| Cash and Cash Equivalents (June 30, 2013) | $34.5 million | $10.4 million (Dec 31, 2012) |
| Short-term Investments (June 30, 2013) | $95.5 million | $0.3 million (Dec 31, 2012) |
| Total Assets | $283.5 million | $151.6 million (Dec 31, 2012) |
| Accumulated Deficit | $(376.2) million | $(321.6) million (Dec 31, 2012) |
Liquidity: As of June 30, 2013, the company held $129.9 million in cash, cash equivalents, and short-term investments. The company raised $150 million in Series F preferred stock during the six months ended June 30, 2013.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 147.6% to $10.8 million for the six months ended June 30, 2013, compared to $4.3 million in the prior year period. This was driven by collaboration revenues, specifically the recognition of deferred revenue from the termination of an ECC with Synthetic Biologics, Inc. and increased R&D service reimbursements.
- Operating Expenses: Total operating expenses decreased 23.1% to $39.0 million from $50.7 million. Research and Development (R&D) expenses dropped 31.4% to $25.1 million due to reduced personnel costs, lower lab supply expenses, and a strategic shift from building inventory to applying technologies for collaborators.
- Other Income/Expense: Total other income (expense) swung from a net gain of $15.9 million in 2012 to a net loss of $14.2 million in 2013. This was primarily due to a $21.6 million unrealized depreciation in the fair value of equity securities (notably Ziopharm Oncology, Inc.), partially offset by a $7.4 million gain on the remeasurement of the previously held investment in AquaBounty upon consolidation.
- Balance Sheet: Total assets increased significantly to $283.5 million, largely due to the addition of $95.5 million in short-term investments and the consolidation of AquaBounty's assets.
Guidance, Outlook, and Risks
Outlook: Management expects to continue incurring significant losses for the foreseeable future. The company anticipates that existing cash, short-term investments, and proceeds from the August 2013 IPO ($168.3 million net) will fund operations for at least the next 12 months. Future capital requirements depend on the progress of R&D, the timing of milestone payments from collaborators, and the commercial success of products.
Management Commentary: The company is transitioning from a focus on building its parts inventory to applying its synthetic biology platforms for specific applications with collaborators. The consolidation of AquaBounty is a strategic move to commercialize genetically modified salmon (AquAdvantage Salmon), though regulatory approval remains pending.
Risks and Contingencies:
- Regulatory Approval: Significant uncertainty exists regarding FDA approval for AquaBounty's AquAdvantage Salmon, which is critical for future revenue in the food sector.
- Collaborator Dependence: Revenue is heavily dependent on Exclusive Channel Collaborations (ECCs). If collaborators fail to develop products or terminate agreements, revenue will be adversely affected.
- Equity Volatility: The company holds significant equity interests in collaborators (e.g., Ziopharm, Synthetic Biologics). Fluctuations in these stock prices directly impact net income through unrealized gains/losses.
- Capital Needs: The company may need additional capital if current plans change or if it is required to fulfill its $29 million remaining purchase commitment for Ziopharm stock.
Investor Verification Checklist
- Regulatory Status of AquaBounty: Verify the current status of the FDA's New Animal Drug Application (NADA) for AquAdvantage Salmon, as this is a primary driver for future commercialization.
- Collaborator Financial Health: Assess the financial stability of key collaborators, particularly Ziopharm Oncology, Inc., which has expressed substantial doubt about its ability to continue as a going concern.
- Deferred Revenue Recognition: Review the terms of ECCs to understand the timing of revenue recognition, as a significant portion of upfront payments is deferred and recognized over time.
- Equity Investment Valuation: Monitor the fair value of equity securities held in collaborators, as market volatility in these stocks creates significant swings in reported net income.
- Post-IPO Liquidity: Confirm the utilization of the $168.3 million IPO proceeds and the company's runway for operations post-IPO.